Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Danyelza Market Size And Revenue Outlook Through 2030
The expansion observed in the past era stems from several factors, including the unfavorable outcomes experienced in relapsed neuroblastoma, significant progress in monoclonal antibody treatments, the granting of orphan drug statuses, enhanced specialization within pediatric oncology, and the successful clinical application of gd2 targeting.
Future growth is expected to be driven by an increase in pediatric cancer studies, the development of more immuno-oncology treatments, improved availability of specialized cancer facilities, favorable reimbursement frameworks, and a heightened understanding of uncommon cancers.
Significant trends anticipated for the forecast period encompass the increasing integration of targeted immunotherapy, a rise in the application of GD2-directed treatments, an expansion of therapeutic options for pediatric oncology, a greater prevalence of combined cancer treatment strategies, and a stronger emphasis on cancers that are resistant or have reoccurred.
Get A Free Sample Report With In-Depth Market Insights:
Danyelza Market Development Factors: What’s Supporting Demand?
A projected rise in pediatric cancer cases is anticipated to stimulate the expansion of the danyelza market moving forward. Pediatric cancers are defined as malignancies occurring in children and adolescents, encompassing various forms such as leukemia, brain tumors, neuroblastoma, and lymphomas. The growing incidence of pediatric cancers can be attributed to factors like advancements in diagnostic techniques, environmental exposures, genetic predispositions, and the long-term effects of cancer treatments. Danyelza (naxitamab) is a targeted immunotherapy designed to help mitigate the prevalence of pediatric cancers through its effective treatment of high-risk neuroblastoma. Its application in conjunction with other therapies has demonstrated improved survival rates and reduced disease progression in young patients facing this aggressive cancer. For instance, according to the Cancer Council, an Australia-based non-profit organization, in October 2024, approximately 93 children aged 0-14 years in Australia died from cancer in 2022. Furthermore, Victoria recorded 206 cancer diagnoses in children under 15 and 263 in those aged 15-24. By 2023, there were 6,197 males and 5,523 females alive who had been diagnosed with cancer during childhood or adolescence. Thus, the increasing prevalence of pediatric cancers is a significant impetus for the growth of the danyelza market.
Danyelza Market Segment Performance And Emerging Opportunities
The danyelza market covered in this report is segmented –
1) By Indication: Neuroblastoma, Osteosarcoma And Other GD2-Positive Cancers
2) By Treatment Type: Monotherapy, Combination Therapy
3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Center
Danyelza Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the danyelza market are concentrating on developing innovative formulations, such as targeted immunotherapy, to enhance therapeutic options and improve patient outcomes. Targeted immunotherapy refers to treatments that utilize substances to specifically identify and attack cancer cells by focusing on proteins or markers, like GD2 in neuroblastoma, thereby enabling the immune system to destroy malignant cells. For example, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotech company, secured marketing authorization from Brazil’s Agência Nacional de Vigilância Sanitária for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, a therapy intended for high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody designed to target GD2, a ganglioside prevalent in neuroectoderm-derived tumors and sarcomas, and was originally developed by Memorial Sloan Kettering Cancer Center under an exclusive license to Y-mAbs.
Danyelza Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the danyelza market are Y-mAbs Therapeutics Inc.
View The Full Danyelza Market Report:
Danyelza Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the danyelza market in 2025. The regions covered in the danyelza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
